Navigation Links
Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation
Date:7/14/2014

g cells and generally have a lower probability of tumor kill. Anti-Angiogenesis compounds typically offer limited survival benefits and cause serious side effects.
  • GenSpera's drug candidates are based on chemical derivatives of a plant cytotoxin, called Thapsigargin, which is a potent inhibitor of the intracellular sarcoplasmic/endoplasmic reticulum calcium ATPase (SERCA) pump. The inhibition of the transport protein causes intracellular Ca2+ (calcium) to rise significantly and trigger apoptosis (cell death). GenSpera masks Thapsigargin's toxicity in the blood stream and delivers and activates it only at the tumor site. 
  • GNSZ's lead candidate, G-202, should be useful against most tumor types. Its first targeted indication is liver cancer, the third largest cancer killer worldwide. G-202 is a prodrug where the active cytotoxin, 12ADT, is masked by a peptide complex until it binds to and cleaved by the targeted Prostate-Specific Membrane Antigen (PSMA), thus triggering apoptosis. Nexavar®, currently the only approved drug for this indication, has more than $700 million in annual sales.
  • G-202 is showing excellent clinical results with Phase IB and early Phase II data in liver cancer, highly suggestive of clinical activity. Only a few easily managed and predictable side effects in Phase 1 were observed. Early Phase II data look promising with a benign side-effect profile and impressive clinical results in advanced liver cancer patients. Phase II clinical trial in liver cancer is ongoing. GNSZ is now using DCE-MRI imaging on newly-enrolled patients (in addition to X-ray), both at baseline and after treatment intervals that the company thinks could demonstrate the decreased blood flow to the tumor, and, thus, the successful killing of the cancerous cells. Typically in this very advanced liver cancer population, the shrinkage of the tumors are not visible on the X-rays due to intense scarring of the tissues.
  • GenSpera's seco
    '/>"/>

  • SOURCE GenSpera, Inc.
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. CVS Caremark Corporation Announces Quarterly Dividend
    2. Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering
    3. Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014
    4. Volcano Corporation Announces Preliminary Fourth Quarter 2013 Revenues; Year-Over-Year Annual Revenues Increase Eight Percent On A Constant Currency Basis
    5. Novartis Pharmaceuticals Corporation stands behind medication adherence activities and reaffirms commitment to patient safety
    6. Heska Corporation to Present at the Sidoti Semi-Annual Micro-Cap Conference
    7. Ramon Martinez Named President of Comprehensive Care Corporation and Elected to the Companys Board of Directors
    8. Dynasil Corporation of America Reports Fiscal Year 2013 Financial Results
    9. Ormco Corporation Files Appeal to the Federal Court Against Ortho Classic H4 Bracket Patent Infringement
    10. EPGL Technology Selected by Major Corporation for Development
    11. Celsion Corporation Announces Combined Clinical Data from Two Phase I Trials at the 2013 San Antonio Breast Cancer Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... 2014   Synageva BioPharma Corp. (NASDAQ: ... therapeutic products for rare disorders, today announced validation ... Marketing Authorization Application (MAA) for sebelipase alfa for ... request for accelerated assessment, which has the potential ... The MAA, and the Biologics License ...
    (Date:12/24/2014)... , Dec. 23, 2014 Tianyin ... company that specializes in patented biopharmaceutical, modernized traditional ... ingredients (API) today announced that the Company achieved ... Good Manufacturing Practice (GMP) certificate of TPI,s Qionglai ... Administration,s (CFDA). The public notice period is a ...
    (Date:12/22/2014)... 22, 2014  CytoSorbents Corporation (OTCQB:CTSOD), a critical ... purification technology to help fight deadly inflammation in ... worldwide, today announced the appointment of Dr. ... its Senior Vice President of Clinical Development, effective ... Di Russo is an accomplished pediatric cardiothoracic ...
    Breaking Medicine Technology:Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5
    ... BRANFORD, Connecticut, June 15, 2011 , ... has killed dozens and,hospitalized thousands across Europe has been ... to generate the,"most accurate and detailed genetic analysis to ... ] ,The sequencing was performed by scientists at the ...
    ... Systems, Inc. (NYSE: VAR ), the world,s ... radiotherapy, announced today it has received Shonin approval from ... to market the TrueBeam™ system for image-guided radiotherapy and ... breast, prostate, head and neck, and other types of ...
    Cached Medicine Technology:Deadly E. Coli Strain Sequenced With Roche GS Junior System by HPA Scientists - Provides Community Most Complete Assembly to Date 2Deadly E. Coli Strain Sequenced With Roche GS Junior System by HPA Scientists - Provides Community Most Complete Assembly to Date 3TrueBeam™ System for Non-Invasive Image-Guided Cancer Treatment Receives Shonin Approval 2TrueBeam™ System for Non-Invasive Image-Guided Cancer Treatment Receives Shonin Approval 3
    (Date:12/25/2014)... Dec. 25, 2014 (HealthDay News) -- The risk of ... holidays, so you need to be extra cautious, an ... we see a significant increase in patients coming in ... the Suffolk County Volunteer Firefighters Burn Center of Stony ... should be full of joy, but if not careful, ...
    (Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. 24, ... a "fountain of youth" drug that can delay the effects ... new study suggests. Seniors received a significant boost to ... genetic signaling pathway linked to aging and immune function, researchers ... experimental medication, a version of the drug rapamycin, improved the ...
    (Date:12/25/2014)... “ SmileStix ” was featured on NewsWatch as part ... mobile applications on the iOS, Android, and Windows markets. Andrew ... the app review and shared with viewers how this is ... old saying goes, “A picture says a thousand words.” It’s ... a single image, because each picture holds a unique and ...
    (Date:12/25/2014)... Each year trauma accounts for approximately ... admissions across the nation (according to the Centers ... National Hospital Ambulatory Medical Care Survey collected data ... 2010. They estimated that there were between 3.5 and ... primary diagnosis of broken bone or fracture. , ...
    (Date:12/24/2014)... (PRWEB) December 25, 2014 Over 700 ... to their local communities. That is 700 smiling little ... single gift. Additionally over $6000 in monetary donations was ... offset some of the expenses they incur through the ... drive were A Child's Haven , Shrine's Children's ...
    Breaking Medicine News(10 mins):Health News:Don't Let Burns Mar Your Holidays 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4Health News:AlignLife Donates Over 700 Toys This Year 2
    ... News) -- Exposure to secondhand smoke could affect hearing ... loss during adolescence, a new study indicates. These ... exposed to secondhand smoke, the researchers warned. Roughly ... exposed to secondhand smoke, reported the study,s authors. These ...
    ... HealthDay Reporter , MONDAY, July 18 (HealthDay ... blood pressure modestly among hypertensive patients, a small, new ... refined carbohydrates -- such as white bread and white ... protein "might be an important component of nutrition intervention ...
    ... JULY 18, 2011 Registration is now open for ... the Cardiovascular Research Foundation, which will return to San ... year, groundbreaking scientific advances in interventional cardiology presented at ... cause of death in the United States, is viewed ...
    ... journal Science Signaling Van Andel Research Institute ... anti-malaria drug chloroquine represses inflammation, which may provide a ... multitude of autoimmune diseases such as arthritis, multiple sclerosis, ... anti-malaria drug that inhibits the growth of parasites. For ...
    ... Researchers at Mount Sinai School of Medicine have identified how ... diabetes, also possibly kills nerve cells in the brain, thereby ... the generation of amyloid-beta (Abeta) in the brain. Abeta plays ... researchers previously linked SorCS1 to Alzheimer,s disease and identified where ...
    ... pace of translating science into real-life solutions for patients ... Health to expand its work over the next five ... (CTSI) is among 10 institutes nationwide to receive the ... first five years of the NIH,s Clinical and Translational ...
    Cached Medicine News:Health News:Secondhand Smoke Linked to Hearing Loss in Teens 2Health News:Small Study Suggests Milk, Soy Proteins Lower Blood Pressure Modestly 2Health News:Small Study Suggests Milk, Soy Proteins Lower Blood Pressure Modestly 3Health News:Innovations in cardiovascular therapies and treatments will be presented at TCT 2011 2Health News:Chloroquine finding may lead to treatments for arthritis, cancer and other diseases 2Health News:Chloroquine finding may lead to treatments for arthritis, cancer and other diseases 3Health News:Researchers identify how a gene linked to both Alzheimer's disease and type 2 diabetes works 2Health News:UCSF receives $112 million to help translate science into cures 2Health News:UCSF receives $112 million to help translate science into cures 3Health News:UCSF receives $112 million to help translate science into cures 4
    ... to its design, this is the ... stone therapy in urinary and biliary ... a multipurpose lithotripter with other applications ... nephrolithotomy. ,The basic system comprises the ...
    All the power and performance of the STS - T but now available with a stand-alone 9" II C-Arm...
    ... Compact Sigma is designed to easily ... precise mechanical coupling eliminates clumsy time ... performed as well. Dorniers patented isocentric ... ,Positioning is simple using the Dornier ...
    The latex free, hydrophilic Self-Cath Plus is designed for single use, intermittent self-catheterization. The unique hydrophilic coating activates immediately upon exposure to water for fast, clean...
    Medicine Products: